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Communicated by Herman M. Kalckar, October 14, 1959 Puromycin' is an antibiotic produced by the actinomycete, Streptomyces alboniger.' It has a broad range of biological activity, being effective against bacteria, protozoa, parasitic worms,3 an alga,4 and cells of mammalian origin.3'5 The site of its action has remained obscure although the compound was shown to be an inhibitor of induced enzyme synthesis. 6 The structure of puromycin has been determined' and confirmed by total synthesis. 8 As can be seen from Fig. la, the antibiotic consists of an aminonucleoside linked to an amino acid. The close structural resemblance between puromycin and the amino acid-bearing end of soluble (or more exactly transfer) ribonucleic acid (S-RNA)9 10 , 11 is shown in Figure 1 . Although the bond between the amino acid and the remainder of the molecule differs in the two compounds, the peptide bond does bear a resemblance to the ester bond. For example, enzymes which catalyze the hydrolysis of one will often catalyze the hydrolysis of the other.'2 The considerations mentioned above suggested to us that the antibiotic action of puromycin is due to an inhibition of protein synthesis, specifically at a site involving transfer RNA.
At least three steps in protein synthesis may be readily distinguished owing to the efforts of a larger number of workers than can be cited here. These steps may be written: 13
(1) AA + ATP + E T. E-AMP-AA + PP (2) E-AMP-AA + S-RNA :i S-RNA-AA + AMP + E (3) S-RNA-AA + Ms GTP -Ms protein + S-RNA. The purpose of this paper is to demonstrate that puromycin, at the low levels required for biological activity, inhibits the incorporation of radioactive amino acid into protein and further to specify its site of action by an examination of the separate steps enumerated above. Our experiments have been confined to a study of the effects of puromycin upon activation and incorporation of leucine in extracts of rat liver.
Materials and Methods. Jagendorf, or L-leucine-U-C14, 50 jiC per mg, purchased from the Schwarz Laboratories. L-leucine and the sodium salt of GDP were purchased from the California Corporation for Biochemical Research. The sodium salt of GTP and the crystalline sodium salt of ATP were obtained from the Pabst Laboratories. The barium salt of phosphoglyceric acid, Schwarz Laboratories, was converted to the sodium salt before use. The sodium salt of phosphocreatine was puchased from the Sigma Chemical Company. Pyrophosphate labeled with p32, prepared by pyrolysis of orthophosphate-P32, was a gift of Dr. M. Bessman. Dr. G. L. Cantoni generously furnished ATP-creatine transphosphorylase, 2.1 mg protein per ml, prepared by the method of Noda et al.,14 and S-RNA-L-leucine-U-C14 containing 2,000 cpm per ml, and having an absorbance of 5 at 260 mnu in a 1 cm light path. The latter material was prepared by Dr. Cantoni and Mr. R. Morrison employing a method to be published. All solutions used in the incubation mixtures were neutralized to approximately pH 7.4. The pH 5 fraction of rat liver was prepared according to Hoagland et a. 1" in the manner prescribed for minimizing base-line exchange. The separation of ATP from PP was effected in the conventional manner.'6 Orthophosphate was determined by the method of Gomori.'7 The measure of exchange used is the specific activity of the ATP expressed as per cent of the value which would have obtained at equilibrium."
Liver extracts for incorporation experiments were prepared essentially according to Keller and Zamecnik."8 Homogenization was carried out in medium A"8 or in cold isotonic sucrose (0.25 M). The supernatant fluid after centrifugation at 15,000g is designated the crude extract and abbreviated "C." The upper portion of supernatant fluid after a further centrifugation for 1 hour at 105,000g in the Spinco preparative ultracentrifuge is designated "S." The remaining microsomal pellet, after rinsing with medium and suspension by gentle homogenization in the previously employed medium (one-third the volume of the crude extract), is designated "M."
Protein was prepared for counting essentially according to Siekevitz."1 Where radioactivity in S-RNA was determined, 0.64 N perchloric acid was substituted for trichloroacetic acid in the initial washes and the RNA hydrolyzed by heating in 0.96 N perchloric acid for 15 minutes at 90°. Protein was removed by low speed centrifugation and a portion of the supernatant fluid neutralized with 2 N KOH at 00. The precipitated KC104 was removed by centrifugation in the cold and one ml of supernatant fluid dried on a 3 cm diam stainless steel planchet. A separate portion was diluted for measurement of absorbance at 260 mju in a Beckman spectrophotometer from which the mg of RNA were calculated.20 Samples were plated at approximately "infinite thinness" as determined from self-absorption curves. Radioactivity was measured with a Nuclear micromil window gas flow counter.
Results.-Demonstration that puromycin inhibts leucine incorporation into protein: When a rat liver extract containing microsomes in addition to the soluble enzymes necessary for amino acid activation and transfer is incubated with ATP, a nucleoside triphosphate-generating system, and radioactive leucine, the protein subsequently isolated is found to be labeled. Previous workers have furnished evidence that this incorporation corresponds to protein synthesis. 1' When low concentrations of puromycin comparable to those required for growth inhibitory activity5 are present in such a system, the incorporation of amino acid is lowered (Table 1 ). In this experiment the antibiotic was preincubated with rat liver extract for 5 min at about 230 before addition of labeled leucine and incubation at 370 (see legend). However, when preincubation was omitted the extent of puromycin inhibition of leucine incorporation was identical. Although this evidence fails to suggest a rate-limiting prior conversion of puromycin to an inhibitory compound, the possibility that a metabolite of puromycin represents the true inhibitor is not excluded. Indeed, cleavage of puromycin at the peptide bond yields an aminonucleoside known to be more active against mammary adenosarcomas in mice than puromycin itself. Effects of the aminonucleoside on the rat liver system are currently under study.
To insure that the inhibitory effects observed require the nucleoside structure of puromycin, the antibiotic was submitted to hydrolysis in 1 N HC1 at 1000 for 20 min, twice the time period required for complete cleavage of the glycosidic bond as measured spectrophotometrically by the shift in extinction maximum in 0.1 N HCl. 7 The hydrolysate was neutralized, and tested on the rat liver system as shown in Table 1 . The absence of inhibition here is consistent with the known absence of biological activity of hydrolysis products of puromycin.7 Mmoles of DL-leucine-1-C14 (0.13 IAC L-leucine-l-C'4 corresponding to approximately 7 X 105 cpm). Tube 7 received 10 jsmoles of NaCl.
Absence of puromycin effect on A TP-generating systems: In separate experiments, similar to the experiment of Table 1 , we have shown that omission of either the energy-generating system or ATP almost entirely eliminates leucine incorporation into protein.
In the experiment of Table 1 , added phosphoglycerate and enzymes present in the crude extract were relied upon to regenerate the required nucleotides, i.e., the added ATP as well as endogenous GTP. In other experiments phosphocreatine was provided as the energy source in the presence of added ATP-creatine transphosphorylase. Puromycin was found to inhibit leucine incorporation into protein equally well independently of the energy-generating system used. Since the inhibitory effects of puromycin on leucine incorporation might be attributed to an inhibition of these energy-generating systems, an experimental test of this hypothesis was undertaken. Under the conditions of the leucine incorporation experiments with crude extracts, added ATP disappeared almost completely after 15 min of incubation even in the presence of an energy-generating system. To determine whether the temporary maintenance of the original concentration of ATP was affected by puromycin, it was necessary to perform the ATP determinations after a shorter period of incubation. An incubation time of 3 min proved to be satisfactory. ATP was determined by the direct and specific method of Strehler and McElroy22 which employs the luminescent system of fireflies.
As can be seen from Table 2 , at least 90 per cent of the ATP added is destroyed within 3 min in the absence of a system to replenish it. Either of the two generating systems permit the original level of ATP to be maintained. The slight increase in ATP concentration with phosphocreatine as energy source may represent phosphorylation of ADP present in the crude extract. Levels of puromycin which completely inhibit leucine incorporation into protein do not affect the ability of either generating system to maintain the original level of ATP. These experiments were performed under the conditions of the leucine incorporation experiments. The results therefore appear to exclude the possiblity that the inhibitory effect of puromycin on leucine incorporation into protein is due to an inhibition of systems responsible for ATP-generation. Absence of puromycin effect on leucine activation: The activation step is the first reaction which leucine undergoes on its pathway into protein. The reaction is conveniently studied by measuring the leucine-dependent incorporation of pp32 into ATP in a "pH 5 fraction" of rat liver extract. 15 It may be seen from Table 3 After 5 min of preincubation at 230 in the absence of PP32, but with 5 jmoles of unlabeled PP, incubation with PP32 was carried out for 15 min at 370 in a final volueme of 1 ml. The incubation mixture contained: L-leucine and puromycin as indicated, 5 ."moles of pp32 (3.1 X 106 cpm), 10 ,moles of KF, 2.4 ;&moles each of ATP and MgCl2, 100 jmoles of tris-(hydroxymethyl)-aminomethane adjusted to pH 7.6, and 0.15 ml of "pH 5 fraction." * Tube 1 received 1 ml of cold 0.73 M trichloroacetic acid immediately after addition of Pp32. t Per cent PP-ATP exchange is the specific activity of the ATP expressed as per cent of the value which would have obtained at equilibrium.
that levels of puromycin completely inhibitory for protein synthesis do not affect the leucine-dependent exchange. This is true at a saturating leucine concentration, and, more important, it is also true at a subsaturating leucine concentration identical to the level of leucine present in the protein synthesis experiment of Table  1 . If puromycin were to interfere with the activation of some amino acid other than leucine we would not expect this to affect leucine incorporation into protein as completely as is the case. Therefore, barring a microsome-dependent conversion of puromycin to an inhibitor of leucine activation, the puromycin inhibition of leucine incorporation into protein cannot be attributed to an affect on amino acid activation.
Absence of puromycin effect on the transfer of leucine to S-RNA: The second reaction which leucine undergoes on its pathway into protein is linkage to a specific transfer RNA present in S-RNA. The reaction was studied by analyzing the RNA of the 105,000g supernatant fluid for radioactivity subsequent to incubation with labeled leucine. In the absence of microsomes protein does not become labeled (Table 4) . Radioactive leucine attached to the S-RNA was liberated from unlabeled protein by treatment with hot HCl04 (see Methods). Puromycin was found to have no effect on the extent of labeling of S-RNA. This is true when the antibiotic was present at concentrations that result in essentially complete inhibition of leucine incorporation into the protein of the same rat liver when a crude extract is incubated with radioactive leucine (Table 4) .
Under the conditions of our experiments, the endogenous S-RNA becomes labeled very rapidly, the process proceeding to completion within 45 seconds from the start of incubation whether or not puromycin (200 mjumoles per ml) is present. Whether puromycin affects the rate of S-RNA labeling by radioactive leucine remains to be investigated under conditions where this rate is measurable.
Demonstration that puromycin inhibits transfer of leucine from transfer RNA-leucine to microsomal protein: Since puromycin inhibits the over-all incorporation of leucine into protein but apparently neither its activation nor attachment to transfer RNA, we were led to expect an effect of puromycin between transfer RNA-leucine and protein. This expectation was confirmed by the experiment of Table 5 . A level of puromycin which reduces the incorporation of free leucine into the protein of a crude extract by 65 per cent causes equivalent inhibition when the starting material is leucine bound to its transfer RNA. This result is not due to any release of leucine from S-RNA into the free state since identical incorporation from bound leucine occurs when unlabeled free leucine is present in 25,000-fold excess. When the crude extract is replaced by a microsomal preparation comparable results are obtained. As with the over-all incorporation of free leucine into protein, it can be shown that the partial reaction studied here is insensitive to acid-hydrolyzed puromycin. These experiments demonstrate that the inhibitory effect of puromycin on leucine incorporation into protein may be accounted for as an inhibition of the transfer of S-RNA-bound leucine into protein.
Discussion.-The wide variety of plant and animal material showing growth inhibition by puromycin suggests that the antibiotic interferes with some major biochemical process not differing in detail from one organism to another. Two considerations call attention to the protein synthetic mechanism as a possible site of action for the antibiotic. First, the observation of Creaser that induced f3-galactosidase synthesis in Staphylococcus aureus is completely inhibited by low levels of puromycin. Second, the structural resemblance between puromycin and the functional end of apparently ubiquitous intermediates in protein synthesis, the transfer RNAs.
Experiments with labeled leucine conform to our expectation that puromycin interferes with protein synthesis. The site of this interference appears to be largely, if not entirely, beyond the formation of transfer RNA-leucine. Our experiments on the two reactions necessary for leucine attachment to transfer RNA do not permit us to exclude a puromycin effect on either of these reactions which is dependent upon the presence of microsomal particles. However, the fact that we can (uantitatively account for inhibition of the over-all reaction by the inhibitory effect of puromycin on a subsequent step shows that at least the early reactions are not inhibited by puromycin to the point where they become rate-limiting.
It is interesting to note that administration of the aminonucleoside of puromycin to rats induces a nephrotic syndrome.24 Examination of the effects of the aminonucleoside on amino acid incorporation may suggest a biochemical basis for this observation. Such studies may also shed light on whether puromycin must be degraded, e.g., to the aminonucleoside, or built into some cellular metabolite. before it becomes inhibitory. If they occur, these reactions must be relatively fast since they appear to be complete before appreciable leucine has been incorporated into protein, a process which itself goes to completion within a few minutes.
Recent evidence indicates that reaction 3 of the protein synthetic pathway may be resolved into a GTP-stimulated passage of transfer RNA-amino acid (or some portion thereof bearing the amino acid) into the microsome,'3 25-27 and a second step which brings about the incorporation of the bound amino acid into protein.
It is hoped that the site of puromycin action may be further localized by separate examination of these two steps.
Two additional antibiotics appear to resemble puromycin in their site of action. Experiments by Lacks and Gros28 and by Hopkins29 suggest that chloramphenicol inhibits amino acid transfer from S-RNA to protein. A recently reported inhibition by dihydrostreptomycin of amino acid incorporation into mycobacterial protein in vivo3" and in vitro,31 again appears to be due to a failure in the protein synthetic pathway at this step.31 Examination of other antibiotics, in particular those for which a cross-resistance develops to the antibiotics mentioned above, may reveal additional inhibitors acting at a similar site.
Summary.-(1) Structural similarities between the broad-spectrum antibiotic puromycin (6-dimethylamino-9-[3'-deoxy-3 '-(p-methoxyl-L-phenylalanylamino)-$-D-ribofuranosyllpurine) and the amino acid-bearing end of S-RNA are discussed.
(2) Puromycin was found to inhibit the incorporation of leucine-C14 into protein in a cell-free preparation from rat liver. (3) Puromycin does not inhibit the rate of ATP-generation by either of two enzyme systems used in the leucine incorporation experiments. It does not inhibit the rate of leucine activation by the "pH 5 fraction" of rat liver. No puromycin inhibition of the extent of S-RNA labeling with leucine-C14 could be detected. (4) The transfer of leucine-C14 from S-RNAleucine-C'4 to protein is inhibited by puromycin. The extent of this inhibition is considered sufficient to account for the inhibition by puromycin of leucine incorporation into protein. (5) Observations of other workers which suggest a similar site of action for the antibiotics chloramphenicol and dihydrostreptomycin are briefly discussed.
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